A friend sent me this link to Stanford Research Institute's work in the development of an anti-angiogenic molecule, SR16388. Studies show that this molecule prevents angiogenesis (or new blood vessel development) and the growth of multiple myeloma cells. The new molecule is currently under development and is getting ready for early patient clinical trials. Click Here to read the SRI International article.